Clinical Study
Real-World Experience with Dolutegravir-Based Two-Drug Regimens
Table 1
Patient demographics and clinical characteristics.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fourteen patients did not have virologic data and could not be classified as nonsuppressed or suppressed. The suppressed and nonsuppressed virologic categories are determined prior to initiation of the DTG 2DR regimen. Additional patient characteristic data were not known for 11 patients (4.0%). More than 1 characteristic could be selected for each patient case; characteristics selected were based on patient records and/or the opinion of the principal investigator or study site designee completing the eCRF. Use of multiple medications by a patient. Data were available for only N = 125 patients. Data presented for 5 most frequent ARTs (N = 272; nonsuppressed: n = 145, suppressed: n = 116, and data not available: n = 11). Also includes the drug combined with cobicistat or ritonavir. Data for suppressed (<50 copies/mL) patients were not available. Data were not available for 10 patients. 2DR, 2-drug regimen; ART, antiretroviral treatment; DRV, darunavir; DTG, dolutegravir; FTC, emtricitabine; MVC, maraviroc; RAL, raltegravir; RPV, rilpivirine; SD, standard deviation; TDF, tenofovir disoproxil fumarate. |